The DOI matches its Crossref record; 217 of the 217 references it cites were found in a registry or an index.
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Open accessAbstract
Dipeptidyl peptidase-4 (DPP4) is a widely expressed enzyme transducing actions through an anchored transmembrane molecule and a soluble circulating protein.Both membrane-associated and soluble DPP4 exert catalytic activity, cleaving proteins containing a position 2 alanine or proline.DPP4-mediated enzymatic cleavage alternatively inactivates peptides or generates new bioactive moieties that may exert competing or novel activities.The widespread use of selective DPP4 inhibitors for the treatment of type 2 diabetes has heightened interest in the molecular mechanisms through which DPP4 inhibitors exert their pleiotropic actions.Here we review the biology of DPP4 with a focus on: 1) identification of pharmacological vs physiological DPP4 substrates; and 2) elucidation of mechanisms of actions of DPP4 in studies employing genetic elimination or chemical reduction of DPP4 activity.We review data identifying the roles of key DPP4 substrates in transducing the glucoregulatory, anti-inflammatory, and cardiometabolic actions of DPP4 inhibitors in both preclinical and clinical studies.Finally, we highlight experimental pitfalls and technical challenges encountered in studies designed to understand the mechanisms of action and downstream targets activated by inhibition of DPP4.(Endocrine Reviews 35: 992-1019, 2014) I. Introduction II.Molecular Biology of DPP4 A. Discovery, genomic organization, and superfamily of related enzymes B. Molecular function C. Regulation of DPP4 expression D. Post-translational modifications of DPP4 III.DPP4 Substrates A. Brain natriuretic peptide (BNP) B. Erythropoietin C. Eotaxin D. Gastrin-releasing peptide (GRP) E. Glucagon F. Glucagon-like peptide-1 (GLP-1) G. Glucagon-like peptide-2 (GLP-2) H. Glucose-dependent insulinotropic polypeptide (GIP) I. Granulocyte colony-stimulating factor (G-CSF) J. Granulocyte-macrophage CSF (GM-CSF) K. GHRH and IGF-1 L. High-mobility group box 1 (HMGB1) M. Macrophage-derived chemokine (MDC) N. Macrophage inflammatory protein-1 ␣ (MIP-1 ␣), chemokine (C-C motif) ligand 3-like 1 (CCL3L1), or LD78 O. Oxyntomodulin P. Pituitary adenylate cyclase-activating polypeptide (PACAP) Q. Neuropeptide Y (NPY) R. Peptide tyrosine tyrosine (PYY) S. Regulated on activation, normal T cell expressed and secreted (Rantes) T. Stromal cell-derived factor-1 (SDF-1) U. Substance P (SP) IV.Discovery of DPP4 as a Drug Target A. Selective DPP4 inhibitors, glucoregulatory substrates, and the treatment of type 2 diabetes B. Metabolic phenotypes in animal models of DPP4 deficiency V. Mechanism(s) of Action of DPP4 Inhibitors A. Selectivity of DPP4 inhibitors B. Mechanisms through which DPP4 inhibitors lower glucose C. Proof of concept and mechanisms for DPP4-dependent glucose control in humans
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Self-citationMENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124 · cited 3×
“Infusion of [125 GIP [1–42] or [125 GLP-1 [7–36]NH2 into DPP4 rats resulted in substantially less N-terminal cleavage of these peptides (90), illustrating the critical role of DPP4 for incretin inactivation in vivo.”
BackgroundPituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery
Vaudry, D., Falluel-Morel, A., Bourgault, S., Basille, M., Burel, D., Wurtz, O., Fournier, A., Chow, B. K. C., Hashimoto, H., Galas, L., et al. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001370 · Cited by 1,058
Lambeir, A.-M., Durinx, C., Scharpé, S., & De Meester, I. (2003) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/713609354 · Cited by 955 · cited 2×
“Plasma from wild-type (but not Fischer 344) rats cleaves recombinant SP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] to generate SP [3] [4] [5] [6] [7] [8] [9] [10] [11] and SP [5] [6] [7] [8] [9] [10] [11] , via mechanisms sensitive to the DPP4 inhibitor diprotin A (131) .”
BackgroundInduction of intestinal epithelial proliferation by glucagon-like peptide 2.
Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880
Self-citation
Cited by
Adipokines in health and disease
Fasshauer, M., & Blüher, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.014 · Cited by 1,050
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Targeting adipose tissue in the treatment of obesity-associated diabetes
Kusminski, C. M., Bickel, P. E., & Scherer, P. E. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.75 · Cited by 678
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Self-citationFluorogenic probes for disease-relevant enzymes
Zhang, J., Chai, X., He, X.-P., Kim, H.-J., Yoon, J., & Tian, H. (2019) · Chemical Society Reviews · doi:10.1039/c7cs00907k · Cited by 606
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Self-citationAnxiety, depression, and the microbiome: A role for gut peptides
Lach, G., Schellekens, H., Dinan, T. G., & Cryan, J. F. (2018) · Neurotherapeutics · doi:10.1007/s13311-017-0585-0 · Cited by 573
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577
Self-citationObesity and diabetes as high‐risk factors for severe coronavirus disease 2019 (Covid‐19)
Zhou, Y., Chi, J., Lv, W., & Wang, Y. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3377 · Cited by 490
Röhrborn, D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00386 · Cited by 440
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Deacon, C. F. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00080 · Cited by 428
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications
Drucker, D. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa011 · Cited by 399
Self-citationDipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
Deacon, C. F. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0399-8 · Cited by 398
Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication
Funcke, J.-B., & Scherer, P. E. (2019) · Journal of Lipid Research · doi:10.1194/jlr.r094060 · Cited by 327
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
“36) were abolished by pre-treatment with a DPP-4 inhibitor, suggesting that GLP-1(7-36) is pro-peptide for GLP-1(9-36) in this setting (67).”
BackgroundMethodInfluentialSelf-citationCardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
Scheen, A. J. (2018) · Circulation Research · doi:10.1161/circresaha.117.311588 · Cited by 286
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153
TCF1 links GIPR signaling to the control of beta cell function and survival
Campbell, J. E., Ussher, J. R., Mulvihill, E. E., Kolic, J., Baggio, L. L., Cao, X., Liu, Y., Lamont, B. J., Morii, T., Streutker, C. J., et al. (2016) · Nature Medicine · doi:10.1038/nm.3997 · Cited by 142
Self-citationTargeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Campbell, J. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101139 · Cited by 133
“Importantly, research on incretin physiology has produced two classes of antidiabetic drugs: i) GLP-1R agonists and ii) inhibitors of dipeptidyl peptidase 4 (DPP4), the enzyme that cleaves and inactivates both incretin peptides [5].”
BackgroundMulvihill, E. E., Varin, E. M., Gladanac, B., Campbell, J. E., Ussher, J. R., Baggio, L. L., Yusta, B., Ayala, J., Burmeister, M. A., Matthews, D., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.10.007 · Cited by 102
Self-citationGlucagon-like peptide-1 receptor action in the vasculature
Almutairi, M., Al Batran, R., & Ussher, J. R. (2019) · Peptides · doi:10.1016/j.peptides.2018.09.002 · Cited by 99
The Emerging Role of Polyphenols in the Management of Type 2 Diabetes
Wang, Y., Alkhalidy, H., & Liu, D. (2021) · Molecules · doi:10.3390/molecules26030703 · Cited by 88
Tian, S., Jiang, J., Wang, J., Zhang, Z., Miao, Y., Ji, X., & Bi, Y. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3673 · Cited by 79
Sick fat: the good and the bad of old and new circulating markers of adipose tissue inflammation
Barchetta, I., Cimini, F. A., Ciccarelli, G., Baroni, M. G., & Cavallo, M. G. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01052-3 · Cited by 77
Incretin‐Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes
Faillie, J., Yin, H., Yu, O. H. Y., Herrero, A., Altwegg, R., Renoux, C., & Azoulay, L. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2430 · Cited by 67
FGF21 Is an Insulin-Dependent Postprandial Hormone in Adult Humans
Samms, R. J., Lewis, J. E., Norton, L., Stephens, F. B., Gaffney, C. J., Butterfield, T., Smith, D. P., Cheng, C. C., Perfield, J. W., Adams, A. C., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01257 · Cited by 65
Bea, S., Son, H., Bae, J. H., Cho, S. W., Shin, J., & Cho, Y. M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15292 · Cited by 64
Evolving Concepts and Translational Relevance of Enteroendocrine Cell Biology
Drucker, D. J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3449 · Cited by 63
Self-citationGlucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Son, J. W., & Lim, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1940 · Cited by 33
Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors
Deacon, C. F. (2020) · Peptides · doi:10.1016/j.peptides.2019.170196 · Cited by 31
Wean, J., Kowalsky, A. H., Laker, R., Will, S., Drucker, D. J., Rhodes, C. J., & Seeley, R. J. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102074 · Cited by 28
Self-citationWallia, A., Prince, G., Touma, E., El Muayed, M., & Seley, J. J. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01366-0 · Cited by 23
Sun, L., Zheng, Z.-M., Shao, C.-S., Zhang, Z.-Y., Li, M.-W., Wang, L., Wang, H., Zhao, G.-H., & Wang, P. (2022) · Pharmaceuticals · doi:10.3390/ph15060740 · Cited by 17
“The process from the production of GLP-1 to the final inactivation is extremely rapid, occurring within only 1.5-2 minutes(Davidson 2009; Mulvihill and Drucker 2014).”
BackgroundInfluentialGuan, C., Luo, J., Li, S., Tan, Z. L., Wang, Y., Chen, H., Yamamoto, N., Zhang, C., Lu, Y., Chen, J., et al. (2023) · ACS Omega · doi:10.1021/acsomega.3c05571 · Cited by 13
Metadata
- Authors
- Mulvihill, E. E., & Drucker, D. J.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2014-09-12
- Volume
- 35
- Issue
- 6
- Pages
- 992-1019
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2131821161
- Cited by
- 609
- References
- 217
- FWCI
- 15.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.